In a clinical trial, patients with nonsteroidal aromatase inhibitor-refractory, recurrent, or metastatic HR+/HER2− breast cancer were given pilaralisib or voxtalisib in combination with letrozole tablets. Here, CYP19A1 is linked to breast cancer.